EsoBiotec SA, a biotechnology company specializing in in vivo cell therapies, has announced a definitive agreement to be acquired by AstraZeneca PLC (NYSE:AZN). The agreement represents a major step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback